Subscribe to our Newsletters !!
Infections pose an everpresent threat to society a
Biotech Fluidics has introduced a durable dual sta
A new COVID-19 variant, BA.3.2, informally called
The sustained tensions between Iran and the United
For a number of years now, healthcare systems glob
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to a fresh and forward-lo
Drug major Glenmark Pharma on Thursday said it has received final acceptance from the US health regulator for central nervous system stimulant medication Amphetamine Sulfate tablets.
The approved product is a generic version of Evekeo tablets of Arbor Pharmaceuticals LLC.
Quoting IQVIA sales statistics for the 12 month period ending November 2020, Glenmark said Evekeo Tablets, 5 mg and 10 mg marketplace achieved annual sales of approximately USD 21.5 million.
Glenmark”s current portfolio consists of 168 products authorised for distribution in the US market and 43 ANDA”s pending approval with the USFDA.
Shares of Glenmark Pharma were trading 1.44 per cent lower at Rs 478.50 apiece on BSE.
